GeoVax Labs, Inc. (GOVX)
| Market Cap | 2.99M -83.2% |
| Revenue (ttm) | n/a -37.1% |
| Net Income | -20.43M |
| EPS | -8.75 |
| Shares Out | 7.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 206,880 |
| Open | 0.4100 |
| Previous Close | 0.4185 |
| Day's Range | 0.4000 - 0.4185 |
| 52-Week Range | 0.4000 - 17.7400 |
| Beta | 3.65 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+2,367.92%) |
| Earnings Date | Jul 27, 2026 |
About GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.... [Read more]
Financial Performance
In 2025, GeoVax Labs's revenue was $2.49 million, a decrease of -37.06% compared to the previous year's $3.95 million. Losses were -$21.46 million, -14.11% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for GOVX stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 2,367.92% from the latest price.
News
GeoVax Labs Proxy statement: Proxy filing
GeoVax Labs filed a proxy statement on September 10, 2026, providing details for shareholder voting and corporate governance matters.
GeoVax Labs Proxy statement: Proxy filing
GeoVax Labs filed a proxy statement on August 31, 2026, providing details for shareholder voting and corporate governance matters.
GeoVax Labs Slides: Corporate presentation
GeoVax Labs has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
GeoVax Labs Earnings release: Q2 2026
GeoVax Labs released its Q2 2026 earnings on July 27, 2026, summarizing the period's financial results.
GeoVax Labs Quarterly report: Q2 2026
GeoVax Labs has published its Q2 2026 quarterly earnings report on July 27, 2026.
GeoVax Labs Slides: Corporate presentation
GeoVax Labs has posted slides in relation to its latest quarterly earnings report, which was published on July 22, 2026.
GeoVax Labs Transcript: Investor update
GEO-MVA, an MVA-based vaccine for Mpox and smallpox, is advancing to a pivotal phase III trial with an expedited EMA pathway, targeting a $2 billion market with significant unmet demand. Recent funding strengthens the balance sheet, and scalable manufacturing is planned to meet global needs.
GeoVax Labs discontinues development of COVID-19 vaccine candidate
GeoVax Labs (GOVX) announced earlier today a strategic prioritization of its development portfolio to concentrate resources on its lead programs, GEO-MVA and Gedeptin. As part of this decision, the co...
Roth Capital ‘strongly’ agrees with GeoVax ending COVID-19 development
After GeoVax Labs (GOVX) decided to discontinue development of its GEO-CM04S1 COVID-19 vaccine, Roth Capital “strongly” agrees with this decision, noting that it was not due to any safety or…
GeoVax Labs files to sell 7.64M shares of common stock for holders
09:03 EDT GeoVax Labs (GOVX) files to sell 7.64M shares of common stock for holders
GeoVax Labs Registration statement: Registration filing
GeoVax Labs filed a registration statement on May 26, 2026, providing details about a securities offering with the SEC.
3 Penny Stocks to Watch Now, 5/19/26
GeoVax Labs ($GOVX), Roboai ($AIIO), and Sunshine Biopharma ($SBFM) are the three penny stocks to watch on May 19, according to TipRanks’ Penny Stock Screener tool. Penny stocks refer to…
GeoVax Labs Proxy statement: Proxy filing
GeoVax Labs filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
GeoVax Labs Quarterly report: Q1 2026
GeoVax Labs has published its Q1 2026 quarterly earnings report on May 14, 2026.
GeoVax Labs Earnings release: Q1 2026
GeoVax Labs released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
GeoVax Labs Proxy statement: Proxy filing
GeoVax Labs filed a proxy statement on May 8, 2026, providing details for shareholder voting and corporate governance matters.
GeoVax Labs Proxy statement: Proxy filing
GeoVax Labs filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
GeoVax Labs price target lowered to $10 from $14 at Roth Capital
Roth Capital lowered the firm’s price target on GeoVax Labs (GOVX) to $10 from $14 and keeps a Buy rating on the shares. GeoVax ended Q4 with limited cash and…
GeoVax Labs Registration statement: Registration filing
GeoVax Labs filed a registration statement on April 16, 2026, providing details about a securities offering with the SEC.
GeoVax Labs Registration statement: Registration filing
GeoVax Labs filed a registration statement on April 16, 2026, providing details about a securities offering with the SEC.
GeoVax Labs Proxy statement: Proxy filing
GeoVax Labs filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
GeoVax Labs files to sell 1.27M shares of common stock for holders
06:04 EDT GeoVax Labs (GOVX) files to sell 1.27M shares of common stock for holders
GeoVax Labs files to sell 865,804 shares of common stock for holders
06:05 EDT GeoVax Labs (GOVX) files to sell 865,804 shares of common stock for holders
GeoVax Labs Annual report: Q4 2025
GeoVax Labs has published its Q4 2025 annual report on April 15, 2026.
GeoVax Labs Earnings release: Q4 2025
GeoVax Labs released its Q4 2025 earnings on April 15, 2026, summarizing the period's financial results.